Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Rating of “Moderate Buy” by Brokerages

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has earned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $18.00.

Several equities analysts have commented on TVRD shares. Wall Street Zen downgraded shares of Tvardi Therapeutics to a “strong sell” rating in a report on Saturday, July 18th. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, July 8th. HC Wainwright began coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 target price for the company. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, July 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th.

Institutional Trading of Tvardi Therapeutics

Several institutional investors have recently added to or reduced their stakes in TVRD. Geode Capital Management LLC acquired a new position in Tvardi Therapeutics in the 2nd quarter valued at $2,617,000. JPMorgan Chase & Co. bought a new stake in shares of Tvardi Therapeutics in the second quarter valued at about $39,000. New York State Common Retirement Fund bought a new stake in shares of Tvardi Therapeutics in the second quarter valued at about $92,000. Marshall Wace LLP bought a new stake in shares of Tvardi Therapeutics in the second quarter valued at about $583,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Tvardi Therapeutics in the second quarter valued at about $43,000. 44.66% of the stock is currently owned by institutional investors.

Tvardi Therapeutics Stock Down 3.8%

TVRD opened at $2.02 on Thursday. Tvardi Therapeutics has a 12-month low of $1.50 and a 12-month high of $43.65. The business has a 50 day moving average of $2.73 and a 200-day moving average of $3.35. The stock has a market cap of $18.95 million, a price-to-earnings ratio of -0.65 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). As a group, analysts expect that Tvardi Therapeutics will post -2.32 earnings per share for the current year.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.